A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis (Q35042658)

24229079

6 August 2017

title

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis (English)

1 reference

6 August 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24229079%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Daniel J Bratton

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24229079%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Mahesh K B Parmar

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24229079%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

14 November 2013

1 reference

24229079

BMC Medical Research Methodology

6 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24229079%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24229079%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24229079%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 2.0 Generic

6 June 2020

copyright license

start time

14 November 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Some recommendations for multi-arm multi-stage trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

The prevention and treatment of missing data in clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Design issues in randomized phase II/III trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Challenges of Phase III study design for trials of new drug regimens for the treatment of TB.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Some drop-the-loser designs for monitoring multiple doses

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Global tuberculosis drug development pipeline: the need and the reality.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design--a reanalysis of 4 trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Speeding up the evaluation of new agents in cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Multi-arm clinical trials of new agents: some design considerations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Stopping at nothing? Some dilemmas of data monitoring in clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

"Proving the null hypothesis" in clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-13-139

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-13-139

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-13-139

Optimal design of multi-arm multi-stage trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-13-139

Stopping clinical trials early for benefit: impact on estimation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-13-139

Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-13-139

Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840569

25 October 2018

Identifiers

DOI

10.1186/1471-2288-13-139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24229079%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

6 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24229079%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

24229079

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24229079%20AND%20SRC:MED&resulttype=core&format=json